-
Important news
-
News
-
Shenzhen
-
China
-
World
-
Opinion
-
Sports
-
Kaleidoscope
-
Photos
-
Business
-
Markets
-
Business/Markets
-
World Economy
-
Speak Shenzhen
-
Health
-
Leisure
-
Features
-
Culture
-
Travel
-
Entertainment
-
Digital Paper
-
In-Depth
-
Weekend
-
Newsmaker
-
Lifestyle
-
Diversions
-
Movies
-
Hotels and Food
-
Special Report
-
Yes Teens!
-
News Picks
-
Tech and Science
-
Glamour
-
Campus
-
Budding Writers
-
Fun
-
Qianhai
-
Advertorial
-
CHTF Special
-
Futian Today
在线翻译:
szdaily -> News -> 
Projects worth ¥12B clinched at biomedical industry meeting
    2022-07-29  08:53    Shenzhen Daily

    Zhang Yu

    

    JeniZhang13@163.com

    

    A TOTAL of 18 projects worth approximately 12 billion yuan (US$1.77 billion) were signed at the 2022 Shenzhen Biomedical Industry Special Investment Meeting in Pingshan District on Thursday.

    

    It was the first professional investment promotion meeting for industrial clusters held in Shenzhen after the city released guidelines on developing 20 strategic emerging industrial clusters and fostering eight future industries in June.

    

    The meeting, with Yanzi Lake International Convention and Exhibition Center as its main venue, also set up three online subvenues in Hong Kong, Toronto in Canada and Silicon Valley in the U.S.

    

    The meeting attracted over 150 representatives from top domestic and international biomedical enterprises, as well as scholars and experts. It had 300,000 online viewers.

    

    Three executives from renowned biomedical companies, including Lawrence Yuan Tian, chairman of Mevion Medical Systems, Wang Feng, president of Shanghai LePure Biotech, and Yan Tan, co-founder of Xbiome, delivered keynote speeches at the meeting, expressing their personal experiences and expectations around the strategic planning of Shenzhen’s biomedical industry, supporting policies, innovation and entrepreneurship environment, and government services. 

    

    Shanghai LePure Biotech was one of the firms that reached investment deals with the city government. 

    

    “The biomedical industry’s development environment in Shenzhen has improved steadily in recent years, which is quite alluring. We chose Shenzhen as our innovation center in the Guangdong-Hong Kong-Macao Greater Bay Area in an effort to support the growth of the biological sector in the bay area,” Wang said.   

    

    In addition to promoting policies and signing projects, the meeting also saw the news of the approval of the clinical trial of SHEN26, a small-molecule oral medication for COVID treatment.

    

    Zhang Xumu, vice dean of the College of Science at the Southern University of Science and Technology (SUSTech), gave a thorough introduction to the most recent progress in the drug’s research and development. 

    

    The new drug was jointly developed by a local biomedical research institute and two pharmaceutical companies. The clinical trial application has been approved by the National Medical Products Administration.

    

    Shenzhen is one of the first batch of national biomedical industrial bases and national independent innovation demonstration zones. As early as 2009, the city listed biology as an emerging industry. The added value of Shenzhen’s biology and health industry reached 58.96 billion yuan in 2021, according to official statistics.

    

    The meeting was hosted by the Shenzhen Municipal Government and jointly organized by the Shenzhen Municipal Development and Reform Commission and the Shenzhen Municipal Commerce Bureau.


深圳报业集团版权所有, 未经授权禁止复制; Copyright 2010-2020, All Rights Reserved.
Shenzhen Daily E-mail:szdaily@126.com